ArticleJournal of multidisciplinary healthcare2025
Assessment of Variations in HAPS Scores, CaMK II Expression Levels, and Prognostic Outcomes Among AP Patients with Diverse Disease Severities.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the differences in Harmless Acute Pancreatitis Score (HAPS), serum Calcium/Calmodulin-dependent Protein Kinase II (CaMK II) expression, and prognosis among patients with acute pancreatitis (AP) of varying disease severities. Methods: A retrospective analysis was conducted on the clinical data of 103 patients with acute pancreatitis (AP) treated at our hospital between April 2022 and April 2024. According to the revised Atlanta classification and the International Consensus on Definitions (2012), patients were divided into Group A (59 cases, mild cases) and Group B (44 cases, severe cases). The HAPS score was calculated using relevant examination data obtained upon admission. Fasting venous blood samples (5 mL) were collected from all subjects on the morning of the second day after admission, and serum CaMK II expression levels were measured using a double-antibody sandwich method. Patients were followed up for three months from the date of admission to record local complications, systemic complications, and mortality. Receiver operating characteristic (ROC) curves were plotted to analyze the predictive value of HAPS scores and serum CaMK II levels for mild AP and patient prognosis. Results: HAPS scores and serum CaMK II levels were assessed at admission. Severe cases showed significantly higher HAPS and CaMK II levels vs mild (P<0.05). ROC analysis demonstrated combined detection (AUC=0.902) outperformed individual markers (HAPS=0.827; CaMK II=0.773) in predicting mild AP. Both biomarkers progressively increased with complication severity (local < systemic < death, P<0.05), showing predictive value (AUC>0.6) for prognosis. Conclusion: HAPS scores and CaMK II expression levels in AP patients show a gradual increase with the severity of the disease, and both can serve as predictive indicators of disease severity and prognosis in AP patients. Moreover, combined detection of these indicators has a higher predictive efficiency than single-item detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.